Kexing Biopharm Advances GB10 Into Phase I Trial For Neovascular AMD In China
First patient dosed in Phase I study of high concentration bispecific antibody candidate targeting VEGF and Ang 2, with the potential to extend ...
Read the original at BioPharma APAC ↗
- Topics
- China & GeopoliticsHealthcare
- Mentions
- AMDChina
- Tracked via
- “chinese ai advances”